Summary
Amgen Inc. reported its financial results for the quarter and six months ended June 30, 2006. The company experienced a significant drop in net income and earnings per share for the quarter compared to the prior year, largely due to a substantial $1.1 billion write-off of acquired in-process research and development related to the Abgenix acquisition. Despite this one-time charge, total revenues showed robust year-over-year growth, driven by strong performance in key products like Aranesp®, Enbrel®, and Neulasta®/Neupogen®. Financially, Amgen strengthened its balance sheet by issuing $5 billion in convertible notes and repurchasing $3 billion of its common stock. The company also completed the acquisition of Abgenix for approximately $2.1 billion in cash, bolstering its antibody therapeutics pipeline. While significant R&D investment is ongoing, particularly for denosumab, the company maintains confidence in its liquidity and ability to meet future obligations. Investors should monitor the impact of ongoing patent litigation and evolving reimbursement policies on future revenue streams.
Key Highlights
- 1Net income for the quarter ended June 30, 2006, was significantly impacted by a $1.1 billion write-off of acquired in-process R&D related to the Abgenix acquisition, resulting in a sharp decrease compared to the prior year's quarter.
- 2Total revenues for the three and six months ended June 30, 2006, increased by 14% year-over-year, reaching $3.6 billion and $6.8 billion respectively, primarily driven by strong sales of Aranesp®, Enbrel®, and Neulasta®/Neupogen®.
- 3The company completed the acquisition of Abgenix, Inc. on April 1, 2006, for approximately $2.1 billion in cash, which is expected to enhance its antibody-based therapeutics portfolio.
- 4Amgen issued $5.0 billion in convertible notes (2011 and 2013) in February 2006 and concurrently repurchased $3.0 billion of its common stock, alongside purchasing convertible note hedges and selling warrants.
- 5Research and development expenses increased significantly by 39% for the quarter and 32% for the six months, reflecting increased investment in late-stage clinical trials, particularly for denosumab.
- 6The company's effective tax rate for the quarter was exceptionally high at 95.6%, influenced by non-deductible R&D write-offs and the expiration of the federal R&E credit.
- 7Cash, cash equivalents, and marketable securities remained strong at $5.0 billion, with approximately $4.5 billion generated from operations in foreign tax jurisdictions.